203 related articles for article (PubMed ID: 37236398)
21. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
[TBL] [Abstract][Full Text] [Related]
22. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
[TBL] [Abstract][Full Text] [Related]
23. Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib.
Di Federico A; De Giglio A; Sperandi F; Melotti B; Ardizzoni A; Gelsomino F
Anticancer Drugs; 2024 Jan; 35(1):86-88. PubMed ID: 37227039
[TBL] [Abstract][Full Text] [Related]
24. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
25. FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.
Koch AL; Vellanki PJ; Drezner N; Li X; Mishra-Kalyani PS; Shen YL; Xia H; Li Y; Liu J; Zirkelbach JF; Palazov E; Gamarian A; Choo Q; Girčys A; Rohr UP; Fesenko N; Spillman D; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2021 Dec; 27(24):6638-6643. PubMed ID: 34301748
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
27. Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India.
Malik PS; Noronha V; Dabkara D; Maddu VK; Rajappa S; Limaye S; Batra U
Indian J Cancer; 2022 Mar; 59(Supplement):S1-S10. PubMed ID: 35343187
[TBL] [Abstract][Full Text] [Related]
28. Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.
Ahn MJ; Cho BC; Ou X; Walding A; Dymond AW; Ren S; Cantarini M; Jänne PA
J Thorac Oncol; 2022 May; 17(5):718-723. PubMed ID: 35181499
[TBL] [Abstract][Full Text] [Related]
29. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
30. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA; Han JY; Dafni U; Cho BC; Yeo CM; Nadal E; Carcereny E; de Castro J; Sala MA; Bernabé R; Coate L; Provencio Pulla M; Garcia Campelo R; Cuffe S; Hashemi SMS; Früh M; Massuti B; Garcia-Sanchez J; Dómine M; Majem M; Sanchez-Torres JM; Britschgi C; Pless M; Dimopoulou G; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA; Peters S;
Ann Oncol; 2022 Feb; 33(2):181-192. PubMed ID: 34839016
[TBL] [Abstract][Full Text] [Related]
31. The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients.
Maione P; Salvi R; Gridelli C
Curr Oncol; 2024 Feb; 31(2):987-997. PubMed ID: 38392068
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
Yi L; Fan J; Qian R; Luo P; Zhang J
Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
[TBL] [Abstract][Full Text] [Related]
33. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
[TBL] [Abstract][Full Text] [Related]
34. Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non-small cell lung cancer and mutated EGFR.
Vila Pérez A; Alegre-Del Rey EJ; Fénix-Caballero S; Špacírová Z; Rosado Varela P; Olry de Labry Lima A
Support Care Cancer; 2023 Dec; 32(1):67. PubMed ID: 38150163
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Passaro A; Mok TSK; Attili I; Wu YL; Tsuboi M; de Marinis F; Peters S
JAMA Oncol; 2023 Aug; 9(8):1124-1131. PubMed ID: 37166792
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.
Li L; Huang Q; Sun J; Yan F; Wei W; Li Z; Liu L; Deng J
Acta Oncol; 2022 Nov; 61(11):1347-1353. PubMed ID: 36240432
[TBL] [Abstract][Full Text] [Related]
37. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
38. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.
Hardenberg MC; Patel B; Matthews C; Califano R; Garcia Campelo R; Grohe C; Hong MH; Liu G; Lu S; de Marinis F; Pérol M; Soo RA; Stiles BM; Tiseo M; Tsuboi M
ESMO Open; 2022 Oct; 7(5):100572. PubMed ID: 36108559
[TBL] [Abstract][Full Text] [Related]
39. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
[TBL] [Abstract][Full Text] [Related]
40. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]